The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

WASHINGTON — Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, albeit with new conditions. The Food and Drug Administration ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable limitations. Previously available under emergency use authorization for ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...